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The number of institutions implanting DBS has proliferated greatly in the past 5 years.
It is imperative that institutions publish their safety data to set the standard of care and inform referring physicians about institutional-specific surgical morbidity and mortality.
In our ten-year experience, DBS is safe for the treatment of medically-refractory movement disorders. The "perioperative" period was arbitrarily chosen as 2 weeks after implant. "Long term" AEs, therefore, occurred 15 days or more after DBS placement.
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Charts from 3 sources were scrutinized including the PDCMDC, the neurosurgeon's clinic notes, and hospital records.
Transient stimulator-induced symptoms were not included as AEs, as this phenomenon is expected during the programming of a properly placed electrode.
To determine the percentage of patients experiencing an AE, a denominator of 319 was chosen rather than the total number of procedures, 413 (simultaneous bilateral placement, staged procedures, and revisions).
To our knowledge, this is the largest and most diverse population of DBS patients reported from one center (Table 1) .
Although a sizable number of patients experience some type of AE (43.3%), most DBS-related AEs, such as headache or confusion, are benign and transient (Table 2) . Some patients, however, develop more serious AEs, such as dysarthria, worsening gait, or cognitive dysfunction.
In our patient population, serious vascular events were uncommon, occurring in 5/319 (1.6%) patients: 2 ICH, 2 IVH, and 1 SDH.
In large DBS patient populations, seizures are reported to occur in 0.9%-9.1% and infection in 3.7-6.5%. Our complication rates for these two AEs compare favorably: 1.2% and 4.4%, respectively.
One patient (0.3%) in this cohort committed suicide, a complication reported to be as frequent as 4.3%.
Previous investigators report a rate of 4.3-8.4% per electrode-year for hardware-related complications (lead fracture, lead migration, electrode dysfunction, and infections). Using similar methodology, our hardware-related complication rate is only 2.5% per electrodeyear. 
